Global Pompe Disease Treatment

Pompe Disease Treatment Comprehensive Study by Type (Infantile-onset Pompe Disease, Adult-Onset Pompe Disease), Therapy (Enzyme Replacement Therapy, Gene Therapy, Others), End User (Hospitals and Clinics, Research and Academic Institutes) Players and Region - Global Market Outlook to 2026

Pompe Disease Treatment Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
AdvanceMarketAnalytics follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Pompe Disease Treatment Market Study:
Amicus Therapeutics (United States), Audentes Therapeutics(United States), BioMarin Pharmaceutical(United States), EpiVax(United States), Valerion Therapeutics(United States), Oxyrane(United States), Sangamo Therapeutics(United States) and Genzyme (United States)

In the last few years, Global market of Pompe Disease Treatment developed rapidly. Major factors driving the market are The rising prevalence of Pompe disease is one of the major key driving factors of growth.

On the basis of product type, the Pompe Disease Treatment market is segmented by infantile-onset Pompe Disease and Adult-Onset Pompe Disease.

Latest Industry Highlights:
"FDA Approves Genzyme Corporation's Myozyme(R) For All Patients With Pompe Disease; Drug To Carry Warning, Genzyme Corp. reported that the Food and Drug Administration has conceded showcasing endorsement for Myozyme(R) (alglucosidase alfa) in the United States. Myozyme has been endorsed for the treatment of patients with Pompe sickness, a weakening, reformist, and frequently lethal turmoil influencing less than 10,000 individuals around the world. The item is the main treatment ever affirmed for Pompe infection and the first for an acquired muscle issue.".

. The Global Pompe Disease Treatment market is gaining huge competition due to involvement of United States companies that constantly invest in research & development to meet market expectation with new innovation.

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Pompe Disease Treatment market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Pompe Disease Treatment market.
Identification of total players or companies operating in the global market which is further concentrated to a fewer or most impacting players which is considered under the report’s scope. In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Pompe Disease Treatment Manufacturer, Government Regulatory and Research Organizations and End-Use Industry.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • infantile-onset Pompe Disease
  • Adult-Onset Pompe Disease
By Therapy
  • Enzyme Replacement Therapy
  • Gene Therapy
  • Others

By End User
  • Hospitals and Clinics
  • Research and Academic Institutes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The rising prevalence of Pompe disease is one of the major key driving factors of growth
    • 3.3. Market Challenges
      • 3.3.1. Lack of skilled professionals
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Pompe Disease Treatment, by Type, Therapy, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Pompe Disease Treatment (Value)
      • 5.2.1. Global Pompe Disease Treatment by: Type (Value)
        • 5.2.1.1. Infantile-onset Pompe Disease
        • 5.2.1.2. Adult-Onset Pompe Disease
      • 5.2.2. Global Pompe Disease Treatment by: Therapy (Value)
        • 5.2.2.1. Enzyme Replacement Therapy
        • 5.2.2.2. Gene Therapy
        • 5.2.2.3. Others
      • 5.2.3. Global Pompe Disease Treatment by: End User (Value)
        • 5.2.3.1. Hospitals and Clinics
        • 5.2.3.2. Research and Academic Institutes
      • 5.2.4. Global Pompe Disease Treatment Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Pompe Disease Treatment (Price)
      • 5.3.1. Global Pompe Disease Treatment by: Type (Price)
  • 6. Pompe Disease Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Amicus Therapeutics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Audentes Therapeutics(United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. BioMarin Pharmaceutical(United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. EpiVax(United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Valerion Therapeutics(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Oxyrane(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sangamo Therapeutics(United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Genzyme (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
  • 7. Global Pompe Disease Treatment Sale, by Type, Therapy, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Pompe Disease Treatment (Value)
      • 7.2.1. Global Pompe Disease Treatment by: Type (Value)
        • 7.2.1.1. Infantile-onset Pompe Disease
        • 7.2.1.2. Adult-Onset Pompe Disease
      • 7.2.2. Global Pompe Disease Treatment by: Therapy (Value)
        • 7.2.2.1. Enzyme Replacement Therapy
        • 7.2.2.2. Gene Therapy
        • 7.2.2.3. Others
      • 7.2.3. Global Pompe Disease Treatment by: End User (Value)
        • 7.2.3.1. Hospitals and Clinics
        • 7.2.3.2. Research and Academic Institutes
      • 7.2.4. Global Pompe Disease Treatment Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Pompe Disease Treatment (Price)
      • 7.3.1. Global Pompe Disease Treatment by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Pompe Disease Treatment: by Type(USD Million)
  • Table 2. Pompe Disease Treatment Infantile-onset Pompe Disease , by Region USD Million (2015-2020)
  • Table 3. Pompe Disease Treatment Adult-Onset Pompe Disease , by Region USD Million (2015-2020)
  • Table 4. Pompe Disease Treatment: by Therapy(USD Million)
  • Table 5. Pompe Disease Treatment Enzyme Replacement Therapy , by Region USD Million (2015-2020)
  • Table 6. Pompe Disease Treatment Gene Therapy , by Region USD Million (2015-2020)
  • Table 7. Pompe Disease Treatment Others , by Region USD Million (2015-2020)
  • Table 8. Pompe Disease Treatment: by End User(USD Million)
  • Table 9. Pompe Disease Treatment Hospitals and Clinics , by Region USD Million (2015-2020)
  • Table 10. Pompe Disease Treatment Research and Academic Institutes , by Region USD Million (2015-2020)
  • Table 11. South America Pompe Disease Treatment, by Country USD Million (2015-2020)
  • Table 12. South America Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 13. South America Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 14. South America Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 15. Brazil Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 16. Brazil Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 17. Brazil Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 18. Argentina Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 19. Argentina Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 20. Argentina Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 21. Rest of South America Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 22. Rest of South America Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 23. Rest of South America Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 24. Asia Pacific Pompe Disease Treatment, by Country USD Million (2015-2020)
  • Table 25. Asia Pacific Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 26. Asia Pacific Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 27. Asia Pacific Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 28. China Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 29. China Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 30. China Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 31. Japan Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 32. Japan Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 33. Japan Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 34. India Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 35. India Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 36. India Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 37. South Korea Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 38. South Korea Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 39. South Korea Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 40. Taiwan Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 41. Taiwan Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 42. Taiwan Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 43. Australia Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 44. Australia Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 45. Australia Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 46. Rest of Asia-Pacific Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 47. Rest of Asia-Pacific Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 48. Rest of Asia-Pacific Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 49. Europe Pompe Disease Treatment, by Country USD Million (2015-2020)
  • Table 50. Europe Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 51. Europe Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 52. Europe Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 53. Germany Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 54. Germany Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 55. Germany Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 56. France Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 57. France Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 58. France Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 59. Italy Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 60. Italy Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 61. Italy Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 62. United Kingdom Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 63. United Kingdom Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 64. United Kingdom Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 65. Netherlands Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 66. Netherlands Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 67. Netherlands Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 68. Rest of Europe Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 69. Rest of Europe Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 70. Rest of Europe Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 71. MEA Pompe Disease Treatment, by Country USD Million (2015-2020)
  • Table 72. MEA Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 73. MEA Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 74. MEA Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 75. Middle East Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 76. Middle East Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 77. Middle East Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 78. Africa Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 79. Africa Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 80. Africa Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 81. North America Pompe Disease Treatment, by Country USD Million (2015-2020)
  • Table 82. North America Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 83. North America Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 84. North America Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 85. United States Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 86. United States Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 87. United States Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 88. Canada Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 89. Canada Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 90. Canada Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 91. Mexico Pompe Disease Treatment, by Type USD Million (2015-2020)
  • Table 92. Mexico Pompe Disease Treatment, by Therapy USD Million (2015-2020)
  • Table 93. Mexico Pompe Disease Treatment, by End User USD Million (2015-2020)
  • Table 94. Pompe Disease Treatment: by Type(USD/Units)
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Pompe Disease Treatment: by Type(USD Million)
  • Table 104. Pompe Disease Treatment Infantile-onset Pompe Disease , by Region USD Million (2021-2026)
  • Table 105. Pompe Disease Treatment Adult-Onset Pompe Disease , by Region USD Million (2021-2026)
  • Table 106. Pompe Disease Treatment: by Therapy(USD Million)
  • Table 107. Pompe Disease Treatment Enzyme Replacement Therapy , by Region USD Million (2021-2026)
  • Table 108. Pompe Disease Treatment Gene Therapy , by Region USD Million (2021-2026)
  • Table 109. Pompe Disease Treatment Others , by Region USD Million (2021-2026)
  • Table 110. Pompe Disease Treatment: by End User(USD Million)
  • Table 111. Pompe Disease Treatment Hospitals and Clinics , by Region USD Million (2021-2026)
  • Table 112. Pompe Disease Treatment Research and Academic Institutes , by Region USD Million (2021-2026)
  • Table 113. South America Pompe Disease Treatment, by Country USD Million (2021-2026)
  • Table 114. South America Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 115. South America Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 116. South America Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 117. Brazil Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 118. Brazil Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 119. Brazil Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 120. Argentina Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 121. Argentina Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 122. Argentina Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 123. Rest of South America Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 124. Rest of South America Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 125. Rest of South America Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 126. Asia Pacific Pompe Disease Treatment, by Country USD Million (2021-2026)
  • Table 127. Asia Pacific Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 128. Asia Pacific Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 129. Asia Pacific Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 130. China Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 131. China Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 132. China Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 133. Japan Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 134. Japan Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 135. Japan Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 136. India Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 137. India Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 138. India Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 139. South Korea Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 140. South Korea Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 141. South Korea Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 142. Taiwan Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 143. Taiwan Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 144. Taiwan Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 145. Australia Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 146. Australia Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 147. Australia Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 148. Rest of Asia-Pacific Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 151. Europe Pompe Disease Treatment, by Country USD Million (2021-2026)
  • Table 152. Europe Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 153. Europe Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 154. Europe Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 155. Germany Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 156. Germany Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 157. Germany Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 158. France Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 159. France Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 160. France Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 161. Italy Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 162. Italy Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 163. Italy Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 164. United Kingdom Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 165. United Kingdom Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 166. United Kingdom Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 167. Netherlands Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 168. Netherlands Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 169. Netherlands Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 170. Rest of Europe Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 171. Rest of Europe Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 172. Rest of Europe Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 173. MEA Pompe Disease Treatment, by Country USD Million (2021-2026)
  • Table 174. MEA Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 175. MEA Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 176. MEA Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 177. Middle East Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 178. Middle East Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 179. Middle East Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 180. Africa Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 181. Africa Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 182. Africa Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 183. North America Pompe Disease Treatment, by Country USD Million (2021-2026)
  • Table 184. North America Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 185. North America Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 186. North America Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 187. United States Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 188. United States Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 189. United States Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 190. Canada Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 191. Canada Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 192. Canada Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 193. Mexico Pompe Disease Treatment, by Type USD Million (2021-2026)
  • Table 194. Mexico Pompe Disease Treatment, by Therapy USD Million (2021-2026)
  • Table 195. Mexico Pompe Disease Treatment, by End User USD Million (2021-2026)
  • Table 196. Pompe Disease Treatment: by Type(USD/Units)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Pompe Disease Treatment: by Type USD Million (2015-2020)
  • Figure 5. Global Pompe Disease Treatment: by Therapy USD Million (2015-2020)
  • Figure 6. Global Pompe Disease Treatment: by End User USD Million (2015-2020)
  • Figure 7. South America Pompe Disease Treatment Share (%), by Country
  • Figure 8. Asia Pacific Pompe Disease Treatment Share (%), by Country
  • Figure 9. Europe Pompe Disease Treatment Share (%), by Country
  • Figure 10. MEA Pompe Disease Treatment Share (%), by Country
  • Figure 11. North America Pompe Disease Treatment Share (%), by Country
  • Figure 12. Global Pompe Disease Treatment: by Type USD/Units (2015-2020)
  • Figure 13. Global Pompe Disease Treatment share by Players 2020 (%)
  • Figure 14. Global Pompe Disease Treatment share by Players (Top 3) 2020(%)
  • Figure 15. Global Pompe Disease Treatment share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Amicus Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 18. Amicus Therapeutics (United States) Revenue: by Geography 2020
  • Figure 19. Audentes Therapeutics(United States) Revenue, Net Income and Gross profit
  • Figure 20. Audentes Therapeutics(United States) Revenue: by Geography 2020
  • Figure 21. BioMarin Pharmaceutical(United States) Revenue, Net Income and Gross profit
  • Figure 22. BioMarin Pharmaceutical(United States) Revenue: by Geography 2020
  • Figure 23. EpiVax(United States) Revenue, Net Income and Gross profit
  • Figure 24. EpiVax(United States) Revenue: by Geography 2020
  • Figure 25. Valerion Therapeutics(United States) Revenue, Net Income and Gross profit
  • Figure 26. Valerion Therapeutics(United States) Revenue: by Geography 2020
  • Figure 27. Oxyrane(United States) Revenue, Net Income and Gross profit
  • Figure 28. Oxyrane(United States) Revenue: by Geography 2020
  • Figure 29. Sangamo Therapeutics(United States) Revenue, Net Income and Gross profit
  • Figure 30. Sangamo Therapeutics(United States) Revenue: by Geography 2020
  • Figure 31. Genzyme (United States) Revenue, Net Income and Gross profit
  • Figure 32. Genzyme (United States) Revenue: by Geography 2020
  • Figure 33. Global Pompe Disease Treatment: by Type USD Million (2021-2026)
  • Figure 34. Global Pompe Disease Treatment: by Therapy USD Million (2021-2026)
  • Figure 35. Global Pompe Disease Treatment: by End User USD Million (2021-2026)
  • Figure 36. South America Pompe Disease Treatment Share (%), by Country
  • Figure 37. Asia Pacific Pompe Disease Treatment Share (%), by Country
  • Figure 38. Europe Pompe Disease Treatment Share (%), by Country
  • Figure 39. MEA Pompe Disease Treatment Share (%), by Country
  • Figure 40. North America Pompe Disease Treatment Share (%), by Country
  • Figure 41. Global Pompe Disease Treatment: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Amicus Therapeutics (United States)
  • Audentes Therapeutics(United States)
  • BioMarin Pharmaceutical(United States)
  • EpiVax(United States)
  • Valerion Therapeutics(United States)
  • Oxyrane(United States)
  • Sangamo Therapeutics(United States)
  • Genzyme (United States)
Select User Access Type

Key Highlights of Report


Jan 2022 210 Pages 90 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Pompe Disease Treatment Quantitative research analysis
Global Pompe Disease Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"" is seen as one of major influencing trends for Pompe Disease Treatment Market during projected period 2020-2026.
The Concentration Rate of Global Pompe Disease Treatment market is highlighted using HHI Index.
United States Players will contribute the maximum growth of Global Pompe Disease Treatment market throughout the predicted period.

Know More About Global Pompe Disease Treatment Report?

Have a Query? Click Here

Other Related Reports

Medicinal Plant Extract Comprehensive Study by Type (Phytomedicines & Herbal Extracts, Flavors & Fragrances, Essential Oils, Spices), Application (Pharmaceuticals & Dietary Supplements, Cosmetics, Fo...
$ 3650
Myocardial Infarction Drugs Comprehensive Study by Type (Vasodilators {Nitrodilators, ACE Inhibitors, ARBs}, Cardiac depressant drugs {Beta Blockers}, Antiarrhythmics {Anti-thrombotics}, Thrombolytic...
$ 3650
Leiomyosarcoma Drug Comprehensive Study by Type (AL-3818, BGB-290, C-21, Others), Application (Clinic, Hospital, Others), Treatment (Surgery, Radiation therapy, Chemotherapy, Targeted drug therapy) P...
$ 3500
Meningitis Vaccine Comprehensive Study by Type (Meningitis A+C, Meningitis ACWY135, Meningitis B), Application (Medical Care, Healthy, Hospital), Route of Administration (Intramuscular and Subcutaneo...
$ 3650
Rosuvastatin Comprehensive Study by Type (High Purity, Low Purity), Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Stores, Online Stores), Form Type (Capsule, Tablet), Dosage (5 ...
$ 3350
Xeloda Comprehensive Study by Application (Colon Cancer, Rectal Cancer, Breast Cancer, Gastric Cancer, Others), Strength (500mg, 100mg) Players and Region - Global Market Outlook to 2026
$ 3500